Eli Lilly and Company (NYSE:LLY) has returned 36.37% over the last six months, as of October 15. This compares to a 21.5% return for the Insider Monkey Billionaire Index and 15.74% for the State Street SPDR S&P 500 ETF Trust.
Eli Lilly is no longer just a pharmaceutical company benefiting from the popularity of weight-loss drugs. It is building a business around them, from manufacturing capacity and easier access to treatment to a pipeline that could keep patients coming back for years. The opportunity is massive, but the challenge is making sure all that growth translates into lasting profits.
Mounjaro and Zepbound continue to drive most of Lilly’s growth, but the company is also looking to expand its reach with oral drugs, international markets, and treatments beyond obesity. The question is whether these new opportunities can sustain growth as the company’s current blockbusters mature.
Lilly ranks 4th in our list of 10 Best Stocks to Buy for the Next 20 Years. Click HERE to find out other stocks on the list.
Growth Is About Reaching More Patients
One of the more interesting things about Lilly’s business is that its next phase of growth may depend as much on access as on developing better drugs. Management said obesity treatment still reaches only a small share of eligible patients. That leaves considerable room for growth, particularly as insurance coverage improves and Lilly expands into markets where these medicines are still relatively new.
Foundayo, Lilly’s oral obesity drug, could help bring more people into treatment. Not everyone wants a weekly injection, and a pill that is easier to take could broaden the market. Its early sales are still modest, so it is too soon to know how large the opportunity will become. Still, the potential matters because Lilly does not need every new product to replace Mounjaro or Zepbound. It needs to reach patients who might otherwise never use an obesity drug.
Eli Lilly and Company is also investing heavily in manufacturing to keep up with demand, including an additional $4.5 billion for its Indiana facilities. The investment makes sense, but the returns will depend on how quickly the new capacity translates into sales. Building more factories is one thing. Keeping them productive enough to justify the cost is another. Even a successful drug can fall short of expectations if the economics don’t work out.
LLY ranked 1st in our list of the 10 Best Bear Market Stocks to Invest In Right Now. To see which stocks made the list, click HERE.
Can Lilly Grow Without Giving Up Too Much on Price?
There is an important detail behind Lilly’s headline growth. In Q2 2026, revenue increased 48%, driven by a 60% increase in volume. Realized prices, however, fell 13%, partly reflecting lower prices in international markets and changes in the U.S. business. Lower prices aren’t necessarily a bad thing if Lilly can make up for them by selling more treatments and improving production efficiency.
Novo Nordisk remains a serious competitor, and new oral drugs could change the market further. Lilly has a strong position today, but that doesn’t mean it can hold on to its market share or pricing power indefinitely. Much will depend on how its drugs stack up against the competition and whether it can keep up with demand without giving up too much on price.
The company is also trying to build growth beyond obesity. Its immunology, oncology, and neuroscience products collectively grew 121% in Q2. These businesses are much smaller than Mounjaro and Zepbound, but their progress matters. A broader portfolio would give Lilly more ways to grow if competition or pricing eventually slows its obesity franchise.
LLY ranked 5th in our list of the 10 Best Return on Equity (ROE) Stocks to Buy. To see which stocks outranked it, click HERE.
Is LLY’s Valuation Justified?
Lilly’s trailing P/E of 38.64x and forward P/E of 24.39x tell two different stories. The forward multiple is lower because Wall Street expects earnings to rise sharply, with forecasts pointing to roughly a doubling from last year’s level to the next. That expected growth explains much of the gap. It does not, by itself, make the stock cheap or expensive.
The question is how much longer Lilly can sustain this kind of earnings growth. Its existing drugs are still gaining traction, and the additional manufacturing capacity should help it meet demand. Foundayo and retatrutide could provide another boost. If Lilly can keep growing sales without sacrificing too much on margins, the current valuation may be justified. But that depends on earnings continuing to grow fast enough to support it.
There are risks to that outlook. Pricing pressure could offset some of the gains from higher volume, and the company is spending heavily on production, research, and acquisitions. Its second-quarter results also included significant acquired research and development charges, which complicate comparisons between reported earnings and the company’s underlying performance. Investors should therefore look beyond a single year’s EPS and consider what Lilly can earn once its newer products and investments mature.
At 24.39x forward earnings, the market is already expecting substantial progress. That is not automatically an unreasonable price for a company growing this quickly. But the investment case depends on Lilly delivering enough growth over several years to justify the earnings expectations built into the stock. The key is not whether the multiple looks high in isolation. It is whether the business can keep compounding after today’s extraordinary growth becomes a tougher act to follow.
LLY also ranked 1st in our list of the 10 Best Healthcare Stocks to Buy According to Hedge Funds. To see which stocks made the list, click HERE.
Can Lilly Keep Delivering?
Lilly should be able to keep growing, with Mounjaro and Zepbound still reaching new patients. Foundayo and international expansion could provide additional growth into the future, while its pipeline offers opportunities beyond obesity treatment.
Lilly, therefore, has plenty of opportunities to keep growing, and it is trading at a relatively reasonable valuation, especially for long-term investors. However, it needs to keep expanding without letting lower prices and heavy investment eat into the returns for short-term investment viability.
CHECK OUT: 10 Most Promising Technology Stocks to Buy Right Now
Market Sentiment
Hedge fund sentiment strengthened in Q2 2026. The number of hedge funds holding Eli Lilly increased to 152 from 132 in Q1, while the combined value of their positions rose to $17.24 billion from $12.58 billion. Both the number of holders and the value of their holdings increased, suggesting growing institutional interest.
READ NEXT: Recursion (RXRX) Enters New Growth Phase as Sanofi Kicks Off Drug Collab, Shares Soar and Eli Lilly (LLY) Posted 48% Revenue Growth. Why Does the Stock Trade Below Its Average Multiple?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center